Genmab — Juni 2017

flottenschmecker

NICE ligner mere og mere medicinverdenens svar på jyske kvinder - de er ligeglade med, hvad tingene koster. Bare de får en rabat...

E_L

Every month going by gives more proof of the benefits of dara. Even if NICE thinks the cost/benefit is too high at this moment, at some point they will have to approve if Dara PFS is getting longer and longer. It is just a matter of time in my opinion. I dont think Janssen should start discounting too heavily
just yet.

Mcjean

NICE har faktisk et godt ry som værende dygtige til at finde balancen mellem produkt, pris og virkning, at de måske fejler med Darzalex er så en anden sag, men mon ikke når det når en bredere label bliver godkendt

Mcjean

men indtil videre synes de pengene er brugt bedre andre steder end at give denne dyre behandling til ikke ret mange og det er jo så et prioriteringsspørgsmål, som jeg ikke skal gøre mig klog på.

Helge_LarsenPI-redaktør

Sorry Sukker..Sidder i møde. Smed linket for at fortælle at Trump var på banen igen over for medicinpriserne. Ved godt at han ikke har magt som han har agt.

royal

https://clinicaltrials.gov/ct2/show/NCT01946477
Er det ud fra denne her de har søgt?

Bulder

Kite får PR for sin CD19 CAR-T i R/R NHL http://www.targetedonc.com/news/ktec19-granted-priority-review-by-fda-for-nonhodgkin-lymphoma

royal

Sorry, Celgene

JohnW

Kan vi mon stadig forvente at få svar fra FDA i dag/i aften?

Sukkeralf

royal - nope ! this one:

Sukkeralf

ClinicalTrials.gov

(clinicaltrials.gov)

Sukkeralf

i dag eller mandag - en sjælden gang imellem går de et par dage over

royal

Thank you

flottenschmecker

Den her pdufa gør vist markedet lidt nervøst - volumen er helt væk

JohnW

Vi kan nok godt vente nogle dage endnu...når blot det er godt nyt

royal

Timer.....

KWC

Preliminary data shows responses achieved in 11 of 34 evaluable patients with cervical cancer treated with tisotumab vedotin
Next steps in clinical development of tisotumab vedotin in this indication under active consideration

KWC

Genmab Announces Preliminary Cervical Cancer Data from Tisotumab Vedotin Phase I/II Study

KWC

"The preliminary data we see in patients with cervical cancer treated with tisotumab vedotin are encouraging. We believe further development of this novel antibody-drug conjugate may be warranted in cervical cancer and are actively looking into possible next steps," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

KWC

Copenhagen, Denmark; June 16, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today preliminary data from the ongoing Phase I/II study of tisotumab vedotin in solid tumors (GEN701). In Part 2 of the study, 11 of 34 evaluable patients in the cervical cancer cohort achieved a response; with a median time of treatment of 4.9 months, 7 responders are still ongoing or in follow up for progression. The safety profile of tisotumab vedotin was consistent with known MMAE based antibody-drug conjuga